

Cancer of Unknown Primary (Identification of Origin)

Quest Diagnostics' Innovation

Quest Diagnostics now offers an assay that will assist in identifying the primary site of a metastatic cancer. Our gene profile array, PCR-based methodology allows for determination of the primary tumor type based on its molecular profile.

Patients presenting with Cancer of Unknown Primary (CUP) traditionally have a poor prognosis with a short median survival. Traditional imaging and laboratory techniques for determining the primary tumor type are costly (up to \$20,000), may take up to 60 days, and are effective in only 25% of patients^{1,2}. Our new assay will reduce both the time and the cost of diagnosis.

HOW IS THIS ASSAY USED?

- It will identify the site of origin in CUP
- It will help guide the physician in establishing prognosis
- It will assist the physician in determining appropriate therapy

Sensitivity	82%
Specificity	99% ³
Test Code	16107X
Specimen Requirements	Formalin-fixed, paraffin-embedded tumor tissue or fresh frozen tissue sample
Report available	15 days
Client Services Contacts	Quest Diagnostics Nichols Institute Oncology Hotline: 1-800-NICHOLS x2096

1. Martin B, et.al. Medical Care 40: pp IV-104-IV-117. 2003

2. Hainsworth, J Oncology, 14;4, April 2000

3. Data on file at Quest Diagnostics Nichols Institute

P.O. Box 10841
14225 Newbrook Drive
Chantilly, VA 20153-0841
703-802-6900
800-336-3718

33608 Ortega Highway
San Capistrano, CA 92690-6130
949-728-4000
800-642-4657
www.questdiagnostics.com

Quest, Quest Diagnostics, the associated logo, Nichols Institute, and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics.
© 2005 Quest Diagnostics Incorporated.
All rights reserved.
HS0021 12/2005



Nichols Institute